adjuvant

(redirected from Neoadjuvant therapy)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Neoadjuvant therapy: Integrative Medicine

adjuvant

[′aj·ə·vənt]
(pharmacology)
A material that enhances the action of a drug or antigen.
References in periodicals archive ?
This application is based on results from an open-label, randomized, global phase III clinical study (the KATHERINE study), evaluating efficacy and safety of Kadcyla adjuvant therapy compared to Herceptin in almost 1,500 people with HER2-positive early breast cancer who had invasive residual disease in the breast and/or axillary lymph nodes following neoadjuvant therapy including Herceptin.
(30) performed perfusion MRI in a total of 50 patients with rectal carcinoma to determine the role of this technique in the evaluation of treatment response after completion of neoadjuvant therapy. The perfusion parameters used were different from the previous study, and included [K.sup.trans], [k.sub.ep], and [v.sub.e].
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients.
We are highly encouraged by these positive results with adjuvant Kadcyla treatment in people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy, said Sandra Horning, MD, Roches Chief Medical Officer and Head of Global Product Development.
In the study group consisting of 262 men and 14 women, the mean age was 59.8 [+ or -] 8.5 years (between 35 and 79 years) and 47 (17%) patients received neoadjuvant therapy. Either lobectomy or bilobectomy was performed on 161 (58.3%) patients.
In this study, 30 patients out of 62 received neoadjuvant therapy. But if analysed critically 16 out of 25 young aged colorectal carcinoma patients received neoadjuvant therapy, which was more than the older population (14 out of 37).
Hedgehog inhibitors work best as neoadjuvant therapy to shrink large skin cancer tumors prior to excision, Dr.
When comparing the number of lymph nodes retrieved in patients with and without neoadjuvant therapy, the number of lymph nodes was less in those who received neoadjuvant therapy (7.8 [+ or -] 5.1 versus 8.7 [+ or -] 8.7 initially and 14.0 [+ or -] 6.3 versus 15.0 [+ or -] 9.0 following a second look), but the differences were not statistically significant (Table 1).
The objective of our retrospective analysis was to evaluate the safety profile of using TCH-P as neoadjuvant therapy in older postmenopausal women with nonmetastatic HER2-positive breast cancer.
Eckardt et al., "Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas," Journal of Clinical Oncology, vol.
Conversely, those who reached a pCR and had high TIL levels had an excellent prognosis, supporting the addition of TIL level to pCR as a prognostic marker after neoadjuvant therapy with anti-HER2 agents.